Q-Line Biotech IPO
smelistedAbout the company
Incorporated in November 2010, Q-line Biotech is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. Since 2013, the company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs directly or through distributors majorly to diagnostic service providers, hospitals and medical colleges. It has established its brands in 12 years through its R&D, manufacturing capabilities and quality assurance. The company’s operations in IVD Industry include clinical chemistry, haematology, immunodiagnostics, molecular diagnostics and others (POC devices & rapids). Its key manufacturing segments include indigenous manufacturing of reagents including Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids) and supplying/ manufacturing of in-vitro diagnostics (IVD), Pathology equipments & devices. During the Covid-19 pandemic, the company diversified its focus and with the technical collaboration of third-party institutes and through its own R&D team developed a range of Covid testing kits viz. RT-PCR Kits, RNA Extraction Kits, VTM Kits etc. It leverages its R&D capabilities to develop and manufacture a portfolio of differentiated reagent formulations /products. They are currently working on a B2B model and supplying most of products to customers which includes distributors, diagnostic service providers and hospitals. For the Make in India instruments, they are working on the following projects: - Selectra Pro M , Selectra Pro XL, Microlab 300, Medonic M20, KC1 Delta, Innolyte, Slide Stainer, Q-Count 5. Its revenue was ~56 % by Reagents, ~37% by Instruments and ~4.5% from consumables/spares in FY25. Its total revenue came from the domestic market with Uttar Pradesh leading with 72% of total FY25 revenue and the rest of 28% by other states like MP, Rajasthan, Odisha, Kerala, Maharashtra, Gujarat, Delhi, Bihar, Haryana and West Bengal. Clinical chemistry (64%) and hematology (29%) were main sub segments in reagent business in FY25. In the instrument business manufacturing part was 52% and trading part was 48% in FY25.
GMP trend (Grey Market Premium by date)
| Date | GMP (₹) | Est. Listing | Change |
|---|---|---|---|
| 21 May | ₹143 | ₹486 | +2 |
| 20 May | ₹141 | ₹484 | +31 |
| 19 May | ₹110 | ₹453 | +41 |
| 18 May | ₹69 | ₹412 | +69 |
| 17 May | ₹0 | ₹343 | 0 |
Strengths
- Operates in the growing diagnostics and healthcare sector
- Focus on IVD reagents, molecular diagnostics, POCT devices, and pathology equipment
- Strong improvement in profitability and EBITDA margins
- In-house manufacturing and R&D capabilities
- IPO proceeds planned for debt reduction
- Positive grey market premium indicating strong listing sentiment
- Experienced presence in diagnostic products segment
Risks
- High debt levels remain a concern
- Debt-to-equity ratio is relatively elevated
- CRISIL “Issuer Not Cooperating” remark raises governance concerns
- SME IPOs carry high volatility and low liquidity risk
- Revenue growth is relatively flat despite profit growth
- Profit expansion mainly driven by margins rather than strong sales growth
- Large minimum investment size increases retail risk
- Possibility of sharp price swings after listing
- Long-term visibility and governance quality still need monitoring
Financial performance (₹ Cr)
IPO Roadmap / Timeline
IPO Opens
Completed21 May 2026Bidding starts for all investor categories
IPO Closes
Completed25 May 2026Last day to place your bid
Basis of Allotment
Completed26 May 2026Share allotment finalised
Refund Initiation
Completed27 May 2026Refunds credited for non-allottees
Credit to Demat
Completed27 May 2026Allotted shares credited to demat account
Listing on Exchange
Completed29 May 2026Shares list on NSE / BSE
Post-close dates are indicative as per SEBI T+3 listing framework and may change per registrar updates.
Lot size & minimum investment
| Investor Type | Min Lots | Min Shares | Min Amount | Max Lots | Max Amount | Notes |
|---|---|---|---|---|---|---|
| Retail / Individual | 1 | 400 | ₹137,200 | 1 | ₹137,200 | 1 lot only |
| HNI | 2 | 800 | ₹274,400 | 2 | ₹274,400 | Min 2 lots |
Shares reserved per category & allotment probability
| Category | Reservation | Shares Offered | Amount (₹ Cr) | Shares Bid | Subscribed | Allotment % |
|---|---|---|---|---|---|---|
| QIB | 50% | 3,198,804 | 107 | 0 | 0.00x | 100% |
| NII | 15% | 959,641 | 32.1 | 0 | 0.00x | 100% |
| Retail | 35% | 2,239,163 | 74.9 | 0 | 0.00x | 100% |
Retail is a lottery-based allotment when oversubscribed; QIB/NII get pro-rata. Probability ≈ 1 / subscription times (100% if under-subscribed).
